![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Malignant Lymphoma |
Free Subscription
2 Am J Clin Pathol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Malignant Lymphoma is free of charge.
The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of
Mantle Cell Lymphoma in the Bone Marrow.
Am J Clin Pathol. 2022;157:709-717.
PubMed
Abstract available
A Combined Biomarker of Bright CD38 and MYC >/=55% Is Highly Predictive of
Double-/Triple-Hit High-Grade B-Cell Lymphoma.
Am J Clin Pathol. 2022 May 3. pii: 6577222. doi: 10.1093.
PubMed
Abstract available
Risk assessment with low pass whole genome sequencing of cell free DNA before
CD19 CAR T-cells for large B-cell lymphoma.
Blood. 2022 May 5. pii: 485178. doi: 10.1182/blood.2022015601.
PubMed
Abstract available
Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with
chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial
ANHL12P1. Blood. 2021;137(26):3595-3603.
Blood. 2022;139:2726.
PubMed
Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK
cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome.
Blood. 2022;139:2712-2716.
PubMed
A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis
of children and young adults with aggressive infection-related lymphoma in East
Africa "(AI-REAL)".
BMC Cancer. 2022;22:484.
PubMed
Abstract available
Multistaining for a better understanding of lymphoma biology.
Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21590.
PubMed
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of
relapsed plasmablastic lymphoma.
Br J Haematol. 2022 May 4. doi: 10.1111/bjh.18228.
PubMed
End of induction positron emission tomography complete response (PET-CR) as a
surrogate for progression-free survival in previously untreated follicular
lymphoma.
Br J Haematol. 2022 May 2. doi: 10.1111/bjh.18217.
PubMed
Abstract available
Polatuzumab vedotin plus bendamustine and rituximab in patients with
relapsed/refractory diffuse large B-cell lymphoma in the real world.
Eur J Haematol. 2022 May 3. doi: 10.1111/ejh.13784.
PubMed
Abstract available
Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID
seems to play a major mutagenic role in Burkitt lymphoma.
Eur J Immunol. 2022 May 3. doi: 10.1002/eji.202249820.
PubMed
Abstract available
Prognostic and therapeutic significance of XPO1 in T-cell lymphoma.
Exp Cell Res. 2022;416:113180.
PubMed
Abstract available
Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal
nasal-type natural killer/T cell lymphoma.
Haematologica. 2022 May 5. doi: 10.3324/haematol.2021.280349.
PubMed
Abstract available
Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma
after three or more lines of prior therapy: evidence of durable benefit.
Haematologica. 2022;107:1214-1217.
PubMed
Clofarabine increases the eradication of minimal residual disease of primary
B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without
improvement of outcome. Results from the randomized clinical trial 08-09 of the
Cooperative
Haematologica. 2022;107:1026-1033.
PubMed
Abstract available
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Haematologica. 2022;107:1119-1130.
PubMed
Abstract available
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior
Outcomes After CD19-CAR for B-ALL.
J Clin Oncol. 2022;40:932-944.
PubMed
Abstract available
Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation
detected by deep next-generation sequencing.
Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
PubMed
Abstract available
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of
primary Central nervous system lymphoma.
Leuk Lymphoma. 2022 May 2:1-7. doi: 10.1080/10428194.2022.2064996.
PubMed
Abstract available
MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage
repair in diffuse large B-cell lymphoma.
Leukemia. 2022 Apr 29. pii: 10.1038/s41375-022-01565.
PubMed
Abstract available
Autologous or allogeneic hematopoietic cell transplantation for relapsed or
refractory PTCL-NOS or AITL.
Leukemia. 2022;36:1361-1370.
PubMed
Abstract available
Bendamustine: A review of pharmacology, clinical use and immunological effects
(Review).
Oncol Rep. 2022;47.
PubMed
Abstract available
Effects of immune checkpoint inhibitor therapy resumption in patients with
malignant tumors after moderate-to-severe immune-related adverse events.
PLoS One. 2022;17:e0267572.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by